Ondansetron exposure during pregnancy is not associated with risk of congenital malformations: evidence from a meta-analysis
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20222480Keywords:
Antiemetic drugs, Ondansetron, Teratogenicity, Morning sickness, Pregnancy, Fetal outcome, Hyperemesis GravidarumAbstract
Ondansetron is widely used drug for treatment of morning sickness and hyperemesis gravidarum. However, whether exposure to ondansetron during pregnancy is associated with risk of congenital malformations or not remains debatable. The present meta-analysis was performed for published cohort/registry-based studies which evaluated the association between ondansetron exposure and risk of congenital malformations. Major congenital malformations were considered as the primary outcome measure. Specific abnormalities like cardiac malformation, septal defect, cleft lip/palate, hypospadias, and genitourinary abnormalities were considered as secondary outcome measures along with spontaneous abortion/miscarriage, stillbirth, preterm delivery, and low birth weight babies. Pooled analysis was done using the Mantle-Hanzle method, random effect model and were expressed as odds ratio (OR) with 95% CI. Fourteen studies were included in systematic review. There was no significant difference for major congenital malformations [n=12; OR: 1.12 (95% CI: 0.93-1.36), I2=96], septal defect [n=5; OR: 1.39 (95% CI: 1.01-1.91), I2=48%], cleft lip/palate [n=3; OR: 1.11 (95% CI: 0.80-1.53), I2=41%] between ondansetron exposed and control arms. However, a greater number of events were found in control arm than intervention arm for cardiac defect [n=7; OR: 1.26 (95% CI: 1.09-1.45), I2=71%; p=0.002]. We also observed a greater number of events for stillbirth and pre-term labour in control arm than in intervention arm with OR: 1.57 (95% CI: 1.24-1.97); p=0.0001 and OR: 1.33 (95% CI: 1.05-1.69); p=0.02, respectively. This meta-analysis concludes that ondansetron exposure during pregnancy is not associated with any increased risk of major congenital malformations, septal /cardiac defect, cleft lip/palate, spontaneous abortion/miscarriage, stillbirth, pre-term labour and low birth weight babies.
References
Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004;111(9):940-3.
Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int. 2013;2013:909860.
Fejzo MS, MacGibbon KW, Mullin PM. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016;62:87-91.
Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018;131(1):e15-e30.
Parker SE, Van Bennekom C, Anderka M, Mitchell AA. National Birth Defects Prevention Study. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstet Gynecol. 2018;132(2):385-94.
Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134-7.
Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Diaz S, Rasmussen SA. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94(1):22-30.
Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol. 2005;61(12):899-906.
Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814-23.
Zambelli-Weiner A, Via C, Yuen M, Weiner DJ, Kirby RS. First trimester ondansetron exposure and risk of structural birth defects. Reprod Toxicol. 2019;83:14-20..
Bérard A, Sheehy O, Gorgui J, Zhao JP, Soares de Moura C, Bernatsky S. New evidence for concern over the risk of birth defects from medications for nausea and vomiting of pregnancy. J Clin Epidemiol. 2019;116:39-48.
Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018;320(23):2429-37.
Tool to Assess Risk of Bias in Cohort Studies. Available from: https://methods.cochrane.org/bias/ sites/methods.cochrane.org.bias/files/public/uploads/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf. Accessed on 12 February 2022.
Andersen JT, Jimenez-Solem E, Andersen NL, Poulsen HE. Ondansetron use in early pregnancy and the risk of congenital malformations-a register based nationwide cohort study. Pharmacoepidemiol Drug Saf. 2013;22:13-4.
Dormuth CR, Winquist B, Fisher A, Wu F, Reynier P, Suissa S, et al. Comparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort. JAMA network open. 2021;4(4):e215329.
Suarez EA, Boggess K, Engel SM, Stürmer T, Lund JL, Jonsson Funk M. Ondansetron use in early pregnancy and the risk of miscarriage. Pharmacoepidemiol Drug Saf. 2021;30(2):103-13.
Huybrechts KF, Hernandez-Diaz S, Straub L, Gray KJ, Zhu Y, Mogun H, Bateman BT. Intravenous ondansetron in pregnancy and risk of congenital malformations. JAMA. 2020;323(4):372-4.
Lemon LS, Bodnar LM, Garrard W, Venkataramanan R, Platt RW, Marroquin OC, et al. Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect. Int J epidemiol. 2020;49(2):648-56.
Sakran R, Shechtman S, Arnon J, Diav-Citrin O. Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study. Reprod Toxicol. 2021;99:9-14.
Özdemirci Ş, Akpınar F, Bilge M, Özdemirci F, Yılmaz S, Esinler D, et al. The safety of ondansetron and chlorpromazine for hyperemesis gravidarum in first trimester pregnancy. Gynecol Obstet Reprod Med. 2014;20(2):81-4.
American College of Obstetricians and Gynecologists, Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131:e15-e30.
The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69). Royal College of Obstetricians & Gynaecologists. Available from: https://www.rcog. org.uk/en/guidelines-research-services/guidelines/gtg69/ [Last accessed on 22 February, 2022]
Fiaschi L, Nelson-Piercy C, Deb S, King R, Tata LJ. Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study. BJOG Int J Obstet Gynaecol. 2019;126:1201–11.
Taylor LG, Bird ST, Sahin L, Tassinari MS, Greene P, Reichman ME, et al. Antiemetic use among pregnant women in the United States: the escalating use of ondansetron. Pharmacoepidemiol Drug Saf. 2017;26:592–6.
Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. Obstet Gynecol. 2014;124:735-42.
Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014;123:1272-9.
Kashifard M, Basirat Z, Kashifard M, Golsorkhtabar-Amiri M, Moghaddamnia A. Ondansetrone or metoclopromide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Clin Exp Obstet Gynecol. 2013;40:127-30.
Communicating Information about Risks in Pregnancy in Product Labeling for Patients and Providers to Make Informed Decisions about the Use of Drugs during Pregnancy. Available from: https://www.fda.gov/media/110905/download. Accessed on 20 February 2022.
Damkier P, Kaplan YC, Shechtman S, Diav‐Citrin O, Cassina M, Weber‐Schoendorfer C. Ondansetron in pregnancy revisited: assessment and pregnancy labelling by the European medicines agency (EMA) & pharmacovigilance risk assessment committee (PRAC). Basic Clin Pharmacol Toxicol. 2021;128(4):579-82.
